Compare ARAI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARAI | MRKR |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 27.7M |
| IPO Year | N/A | 2010 |
| Metric | ARAI | MRKR |
|---|---|---|
| Price | $0.71 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | ★ 2.4M | 69.6K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $800.66 | N/A |
| Revenue Next Year | $650.00 | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.81 |
| 52 Week High | $15.50 | $4.07 |
| Indicator | ARAI | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 47.45 |
| Support Level | $0.65 | $1.34 |
| Resistance Level | $0.81 | $1.52 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.95 | 34.75 |
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.